A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2023

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.
Epistemonikos ID: f5711b2fa80817d3026313e5bb610932a8b16ac2
First added on: May 14, 2024